Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year

The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.

More from Archive

More from Pink Sheet